NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with…
Presentation also given at the 20th World Congress of the International Pancreas & Islet Transplant Association (IPITA)WALTHAM, Mass., July 09,…
-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301…
Proceeds used to retire $68 million of existing debt with the remainder designated for future growth initiatives Additional facility of…
Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug FilingKANSAS CITY, Kan., July…
Proceeds to support key development milestones, including CMC advancement, initiation of a Phase I clinical trial in the first half…
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term…
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without ToleranceSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo…
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 /…
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1…